After five years of design, two years in development, and now shipping thousands of units to customers, breakthrough psoriasis treatment Prosoria is poised to make its mark in the over-the-counter skin care market.
For the second year, Hy-Vee, Inc. will be providing free biometric screenings throughout its eight-state region during Heart Health Month in February. Hy-Vee dietitians working out of Hy-Vee Healthy You Mobiles will offer the free biometric screenings to customers at 150 Hy-Vee stores.
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Looking ahead to 2019, the pharmacy business is poised to be more disrupted than ever before.
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. For much of 2018, capital markets for biotech investment were strong. Some 53 biotech companies went public with more than $5.
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.
Editor’s note: This is Part I of an article that ran in the 1/21/19 issue of CDR.
Nebraska, New Mexico and Kentucky are in the top slots for State Flu Activity in Walgreens Flu Index for the week ending January 12, 2019.
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives.
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. One thing that can be said about the state of prescription medications in 2019 is that the pharmacy payment model is complex, convoluted and confusing.
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. In health policy, 2018 and 2019 could look a lot alike.
There has been significant focus and attention paid to the issue of drug prices in the last few years. As Adam Fein, president of Pembroke Consulting Inc. and chief executive officer of Drug Channels Institute, has said, “Drugs are 12% of the costs, but 90% of the conversation.
Drug prices are a major target of patient groups and Congress, although drug spending makes up only 10% of the $3.3 trillion spent on U.S. health care in a year.
The consumer packaged goods industry is rapidly evolving, and a New Year will usher in even more changes.
For us, alerting our patients to new ways to boost immunity or rebound from illness quickly is one of the best parts of the job.
Nonalcoholic fatty liver disease (NAFLD) is an asymptomatic disease that affects about 100 million Americans. Being overweight, obese or diabetic are primary risk factors for NAFLD, an umbrella term describing those liver diseases that aren’t related to alcohol consumption.
The days of considering the federal segment a statutory liability with little value proposition to the overall commercial book of business are gone.
